5-丙氧基-1H-吡唑-3-胺 | 1043436-01-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 5-丙氧基-1H-吡唑-3-胺
• 英文名称: 5-propoxy-1H-pyrazol-3-amine
• 英文别名: 3-propoxy-1H-pyrazol-5-amine
• CAS: 1043436-01-6
• 化学式: C₆H₁₁N₃O
• mdl: MFCD11846995
• 分子量: 141.173
• InChiKey: LBTHEZOWTPHGCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  63.9
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-丙氧基-1H-吡唑-3-胺 、 2,4,5-三氯嘧啶 在 三乙胺 作用下， 以 乙醇 为溶剂， 反应 10.0h， 生成 2,5-二氯-N-(5-丙氧基-2H-吡唑-3-基)嘧啶-4-胺
  参考文献：
  名称：

  Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases

  摘要：

  The design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4-aminopyrazolylpyrimidine chemotype. Initial optimization of the series led to more potent Trk inhibitors. Further optimization using two strategies resulted in significant improvement of physical properties and led to the discovery of IN (AZ-23), a potent, orally bioavailable Trk A/B inhibitor. The compound offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.

  DOI：

  10.1021/jm800343j
• 作为产物：
  描述：

  丙醇 、 3-氨基-5-吡唑醇 在 偶氮二甲酸二异丙酯 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 生成 5-丙氧基-1H-吡唑-3-胺
  参考文献：
  名称：

  Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases

  摘要：

  The design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4-aminopyrazolylpyrimidine chemotype. Initial optimization of the series led to more potent Trk inhibitors. Further optimization using two strategies resulted in significant improvement of physical properties and led to the discovery of IN (AZ-23), a potent, orally bioavailable Trk A/B inhibitor. The compound offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.

  DOI：

  10.1021/jm800343j

文献信息

• EP1686999B1
  申请人：——

  公开号：EP1686999B1

  公开（公告）日：2009-07-01
• [EN] NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE CONDENSÉ AZOTÉ<br/>[JA] 含窒素縮合複素環化合物
  申请人：TAISHO PHARMA CO LTD

  公开号：WO2017069270A1

  公开（公告）日：2017-04-27

  ＧＡＢＡＢ受容体ＰＡＭ作用に基づいた、自閉症スペクトラム障害、脆弱性Ｘ症候群、統合失調症、双極性障害、うつ病、不安障害、認知症、疼痛、薬物・アルコール依存症、痙攣、脳血管障害、脳性麻痺、脊髄麻痺、外傷後遺症、多発性硬化症、筋萎縮性側索硬化症、ｓｔｉｆｆ－ｍａｎ症候群、本態性振戦、過活動膀胱、胃食道逆流性疾患又はＣｈａｒｃｏｔ－Ｍａｒｉｅ－Ｔｏｏｔｈ病等の疾患の治療又は予防に有用な新規化合物又はその医薬上許容される塩を提供する。具体的には、式（Ｉ）で示される化合物又はその医薬上許容される塩を提供する。
• Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases
  作者：Tao Wang、Michelle L. Lamb、David A. Scott、Haixia Wang、Michael H. Block、Paul D. Lyne、John W. Lee、Audrey M. Davies、Hai-Jun Zhang、Yanyi Zhu、Fei Gu、Yongxin Han、Bin Wang、Peter J. Mohr、Robert J. Kaus、John A. Josey、Ethan Hoffmann、Ken Thress、Terry MacIntyre、Haiyun Wang、Charles A. Omer、Dingwei Yu

  DOI：10.1021/jm800343j

  日期：2008.8.1

  The design, synthesis and biological evaluation of a series of 4-aminopyrazolylpyrimidines as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4-aminopyrazolylpyrimidine chemotype. Initial optimization of the series led to more potent Trk inhibitors. Further optimization using two strategies resulted in significant improvement of physical properties and led to the discovery of IN (AZ-23), a potent, orally bioavailable Trk A/B inhibitor. The compound offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.